Forrester Introduces The Total Experience Score: A New Metric For Measuring The Power Of A Unified Brand And Customer Experience
Aligning brand and customer experience empowers companies to outperform competitors, achieve up to 3.5x revenue growth, and earn higher customer retention and loyalty
SINGAPORE, June 25, 2025 /PRNewswire/ -- According to Forrester's (Nasdaq: FORR) Global Total Experience Score Rankings, 2025, when companies align their brand promise with the experiences they deliver across both customer and non-customer segments, they are better positioned to win and serve customers — unlocking up to 3.5x revenue growth and significantly boosting customer loyalty. Forrester's research shows that brand experience (BX) and customer experience (CX) are interconnected. To drive growth, companies need a harmonized framework that evaluates both experiences in tandem.
Forrester's Total Experience Score, a new metric launching today, integrates scores from Forrester's new Brand Experience Index (BX Index™) and its long-standing Customer Experience Index (CX Index™) to generate a single score that reflects how both non-customers and customers perceive a brand. The only metric that measures the impact of brand perceptions across the entire customer lifecycle, the Total Experience Score also provides an in-depth analysis to identify specific actions that companies can take to drive growth.
Key findings from the global Total Experience Score rankings include:
In Asia Pacific, investment firms performed strongly. The top-scoring industries in India and Singapore were investment firms, and in Australia, it was banks. The lowest-scoring industries in this region were banks in India and Singapore and auto home insurers in Australia.
Europe has a large disparity between customers and non-customers. The gap between customer and non-customer scores is wide across Europe — 18 brands scored more than twice as high with customers as non-customers. The top-scoring industry in the region was investment firms in the UK, while the lowest was Swedish banks.
In North America, direct banks excelled while insurers struggled. Direct banks achieved the highest average industry score in both the US and Canada, while the lowest average scores were for health insurers in the US and auto/home insurers in Canada.
To calculate a brand's Total Experience Score, Forrester first analyzed the performance of 413 brands across 10 industries and 13 countries based on how more than 360,000 consumers perceived them. It then determined how these brands fared on the BX Index and CX Index. The interplay between BX and CX is further captured in a "growth grid," Forrester's snapshot of how successful a company is at both winning and serving customers and how it stacks against its peers. Companies that want to grow revenue must align their initiatives along both these vectors: Win new customers and serve existing customers to generate revenue from retention and enrichment. The non-customer and customer components of the Total Experience Score, plotted on the two axes of the growth grid, represent each of these vectors.
"Driving growth requires a dual focus — shaping brand perceptions that inspire consideration and loyalty and strengthening them through consistent, customer-centric experiences," said Keith Johnston, group research director at Forrester. "While BX and CX are powerful revenue drivers individually, when integrated into a cohesive total experience, they amplify one another to deliver even greater financial returns. Companies can use the growth grid as both a diagnostic and prescriptive tool to shape their brand and business strategy. Additionally, this framework allows companies to assess their competitive standing as well as performance across brands within their own portfolio."
Forrester's Total Experience Score, BX Index, and CX Index rankings and results are accessible within the Forrester Decisions portfolio of research services. Clients of Forrester Decisions services for Customer Experience, B2C Marketing Executives, and Digital Business & Strategy have access to the BX Index and CX Index annual benchmarking exercise to measure the interconnectedness between brand and customer experience.
Resources:
Learn more about the Total Experience Score and how it can drive growth.
Read more about the results of Forrester's 2025 global CX Index and explore Forrester's 2025 global CX Index report (client access required).
Visit here to learn more about Forrester's BX Index.
Learn more about Forrester's CX Index, BX Index, and Total Experience Score methodologies.
About Forrester
Forrester (Nasdaq: FORR) is one of the most influential research and advisory firms in the world. We empower leaders in technology, customer experience, digital, marketing, sales, and product functions to be bold at work and accelerate growth through customer obsession. Our unique research and continuous guidance model helps executives and their teams achieve their initiatives and outcomes faster and with confidence. To learn more, visit Forrester.com.
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/forrester-introduces-the-total-experience-score-a-new-metric-for-measuring-the-power-of-a-unified-brand-and-customer-experience-302490381.html
SOURCE Forrester
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Cox Automotive Study Finds Digital Retailing, External Partnerships and AI Key to Dealer Success and Profitability
ATLANTA, June 25, 2025 /PRNewswire/ -- Cox Automotive's Digitization of Automotive Retail Study reveals a growing momentum toward more efficient, connected, and AI-enabled vehicle retailing. As consumer expectations shift, nearly half of franchise dealers now offer a fully online purchase experience—doubling in just two years—marking a decisive industry evolution that also links increased digitization to profitability. The research highlights that 7 in 10 buyers say completing steps online saves time and improves their experience, while 83% of dealers acknowledge customers often repeat steps in-store due to inconsistent online data. To close this gap, high-performing dealers are increasingly turning to third-party partnerships and integrated AI tools. "Forcing car buyers down one purchase path is no longer considered a best practice. Today's most successful dealers are rethinking the retail journey—creating seamless transitions between online and in-store, powered by automation, clean data, and personalization," said Lori Wittman, President of Retail Solutions at Cox Automotive. "This study reinforces our mission to support dealers in building the omnichannel, customer-first experiences consumers now demand. Opening all paths to purchase and connecting them is even more important in this rising cost environment we're all facing." Additional findings include: 62% of dealers use multiple retailing tools, creating challenges around data consistency and integration. High-performing dealers offer more online steps and are 53% more likely to use AI—leading to higher close rates and profitability. While 83% of consumers believe AI will impact future vehicle purchases, only 37% of dealers consider it essential today. The study supports Cox Automotive's omnichannel approach and builds on the company's connected retail ecosystem strategy, showing how modern, connected experiences are not only desired—they're expected- and profitable. For more insights, download the full ebook covering the study, The Omnichannel Dealership: About Cox AutomotiveCox Automotive is the world's largest automotive services and technology provider. Fueled by the largest breadth of first-party data fed by 2.3 billion online interactions a year, Cox Automotive tailors leading solutions for car shoppers, auto manufacturers, dealers, lenders and fleets. The company has 29,000+ employees on five continents and a portfolio of industry-leading brands that include Autotrader®, Kelley Blue Book®, Manheim®, vAuto®, Dealertrack®, NextGear Capital™, CentralDispatch® and FleetNet America®. Cox Automotive is a subsidiary of Cox Enterprises Inc., a privately owned, Atlanta-based company with $23 billion in annual revenue. Visit or connect via @CoxAutomotive on X, CoxAutoInc on Facebook or Cox-Automotive-Inc on LinkedIn. View original content to download multimedia: SOURCE Cox Automotive
Business Wire
33 minutes ago
- Business Wire
Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) will host its inaugural 2025 R&D Day today to highlight its key pipeline programs and their potential to drive long-term growth. Across nine disclosed programs, the Company anticipates initiating seven Phase 2 or Phase 3 studies during 2025-2026. Acadia further anticipates reporting five Phase 2 or Phase 3 study readouts during 2025-2027—underscoring the breadth of its pipeline and the momentum behind its R&D strategy. Q3 2025 - Phase 2 study initiation for ACP-204 in Lewy Body Dementia Psychosis (LBDP) Q3 2025 - Phase 3 study initiation in Japan for trofinetide in Rett syndrome Early Q4 2025 - Topline results for the COMPASS PWS Phase 3 study of ACP-101 in Prader-Willi syndrome (PWS) following the recent completion of enrollment Q4 2025 - Phase 2 study initiation for ACP-211 in major depressive disorder (MDD) Q4 2025 - First in human study of ACP-271 in healthy volunteers Q1 2026 - Potential approval from European Medicines Agency for trofinetide Mid-2026 - Topline results from ACP-204 Phase 2 study in Alzheimer's disease psychosis (ADP) 2026 - Phase 2 study initiation for ACP-711 in Essential Tremor (ET) 'Acadia is building from a position of strength, with two commercial franchises on track to deliver over $1 billion in net sales this year,' said Catherine Owen Adams, Chief Executive Officer. 'As we advance our pipeline, the five molecules we showcase today represent a multibillion-dollar incremental revenue opportunity. They also underscore our unwavering commitment to bold science and our focus on delivering transformative therapies for patients with serious and underserved neurological and rare diseases. We believe the opportunity ahead is extraordinary—and we are confident in our ability to execute with discipline and purpose as we work to build a biotech powerhouse.' 'At Acadia, we're building a strong, sustainable pipeline focused on progressing the most promising science with the goal of meaningfully improving patient care,' said Elizabeth H.Z. Thompson, Ph.D., Executive Vice President, Head of R&D. 'Our pipeline is moving forward with real momentum. Between now and the end of 2026, we plan to initiate seven Phase 2 or 3 studies, with five key readouts anticipated by the end of 2027. We remain deeply committed to advancing care in neurological and rare diseases, leveraging our development expertise and commercial strength to bring meaningful innovation to patients.' The Company will be discussing the following pipeline programs today: ACP-101 (intranasal carbetocin) A long-acting analogue of human oxytocin for the potential treatment of PWS ACP-204 A new, highly selective, potent inverse agonist of 5-HT2A that builds upon lessons learned from pimavanserin for the potential treatment of ADP and LBDP ACP-211 An orally administered, selectively deuterated form of R-Norketamine for the potential treatment of MDD ACP-711 A selective GABA A -α3 modulator targeting the potential treatment of ET ACP-271 A GPR88 agonist for the potential treatment of Tardive Dyskinesia and Huntington's Disease To register for the live webcast, please click here. A replay of Acadia's R&D Day will be available on the company's website, under the investors section for approximately 3 months following the event. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neurological and rare diseases to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at and follow us on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as 'may,' 'will,' 'should,' 'could,' 'would,' 'expects,' 'plans,' 'anticipates,' 'believes,' 'estimates,' 'projects,' 'predicts,' 'potential,' 'continue,' 'opportunity,' 'goal' and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release, include, but are not limited to, statements about: (i) our business strategy, objectives and opportunities, including the timing for and clinical and market potential of our pipeline assets, and potential for enhanced shareholder value; (ii) plans for, including timing, development and progress of commercialization or regulatory timelines for our products, including NUPLAZID and DAYBUE, and our product candidates; (iii) benefits to be derived from and efficacy of our products, including the potential advantages of our products and product candidates; (iv) the timing and conduct of and topline results for our clinical trials, including the timing of topline results from our clinical trial in Prader-Willi syndrome, the continuing enrollment in our clinical trials in Alzheimer's disease psychosis, the initiation of our clinical trial in Lewy Body Dementia Psychosis, and the timing and content of our presentations or announcements regarding our clinical trials; (v) our estimates regarding our future financial performance, profitability, capital requirements or expenses, including estimates of potential commercial product and pipeline peak sales and potential net sales of our commercial franchises in 2025, and (vi) our ability to successfully complete additional business development transactions. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to: our dependency on the continued successful commercialization of our products and our ability to maintain or increase sales of our products; our plans to commercialize DAYBUE globally and trofinetide in the EU; the costs of our commercialization plans and development programs, and the financial impact or revenues from any commercialization we undertake; our ability to obtain necessary regulatory approvals for our product candidates and, if and when approved, market acceptance of our products; the risks inherent with product candidate development, including risks of unsuccessful clinical trial enrollment and negative or inconsistent results; our dependence on third-party collaborators, clinical research organizations, manufacturers, suppliers and distributors; the impact of competitive products and therapies; our ability to generate or obtain the necessary capital to fund our operations; our ability to grow, equip and train our specialized sales forces; our ability to manage the growth and complexity of our organization; our ability to maintain, protect and enhance our intellectual property; and our ability to continue to stay in compliance with applicable laws and regulations. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ, please refer to our annual report on Form 10-K for the year ended December 31, 2024 as well as our subsequent filings with the Securities and Exchange Commission from time to time, including our quarterly report on Form 10-Q for the quarter ended March 31, 2025. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law.
Business Wire
33 minutes ago
- Business Wire
Toshiba Lands Significant National Cooperative Contract
LAKE FOREST, Calif. & FRANKLIN, Tenn.--(BUSINESS WIRE)-- Toshiba America Business Solutions awarded a five-year contract and five-year renewal option with Region 4 – ESC, available through OMNIA Partners. @ToshibaBusiness Awarded cooperative contract with Region 4, available through OMNIA Partners! Agreement provides K-12 schools, universities, nonprofit and government organizations affordable pricing on Toshiba products and services. #TeamToshiba Share This cooperative contract enables OMNIA Partners' members to benefit from rigorously negotiated pricing on Toshiba's award-winning products and services. This means OMNIA Partners members continue receiving volume pricing on Toshiba's innovative e-STUDIO ™ multifunction printers, managed print services, label and receipt printers, digital signage and Elevate Sky ® solutions. Rigorous Vetting Process Cooperative Contracts available through OMNIA Partners are competitively solicited and publicly awarded with cost-optimized vendor agreements. This makes it easier for participating members to select from carefully vetted vendors delivering products and services meeting the specific needs of school districts, universities, government and nonprofit organizations across the United States. "It's our privilege to work alongside OMNIA Partners for 12 years now to help their members affordably accomplish their day-to-day goals through the use of our products and services," states Toshiba America Business Solutions Chief Revenue Officer Steven Sauer. "Our team is very much looking forward to continuing to address the constantly evolving technology needs OMNIA Partners members are seeking." Click-to-Tweet: Toshiba Lands Significant National Cooperative Contract About OMNIA Partners As your ally in the purchasing process, OMNIA Partners is dedicated to optimizing procurement for your organization. Our goal is to improve the way your organization identifies, evaluates, and procures what they need at the best value. With free membership, you'll gain full access to our portfolio of leading national supplier contracts, spend visibility, analytics, and subject matter experts. Join thousands of members who are discovering a better way to buy. Visit About Toshiba America Business Solutions, Inc. Toshiba America Business Solutions is a leading innovator of solutions empowering people to perform efficiently and effectively in their work environment. Serving professionals across the United States, Mexico, and Central and South America, Toshiba delivers secure and sustainable systems, services, and subscriptions to better print, manage, and display information. Toshiba continuously focuses on its clients and communities, is committed to sustainability, and is recognized as a Wall Street Journal Top 100 Sustainable Company. To learn more, please visit Follow Toshiba on LinkedIn, X (Twitter) and YouTube.
